trial falure
UCB and Biogen’s lupus drug falls short at Phase 2b
October 24, 2018Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
